SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are approved for glucose lowering in patients with T2DM along with reducing reno-vascular complications and enhancing weight loss.